EXPERIENCE
Executives & Board of Advisors
Recognized leaders with expertise in cancer and immunity, business development, and therapeutics development
John Letterio, MD
Chief Medical Advisor
John’s extensive career in oncology began at the National Cancer Institute. He is currently Professor of Pediatrics and Chief, Division of Pediatric Hematology/Oncology, Case Western Reserve University and Rainbow Babies & Children’s Hospital (Cleveland, OH). He serves as Co-Director of the Developmental Therapeutics Program of the Case Comprehensive Cancer Center and will guide the clinical operation of TTX’s FDA approval work.
Paul E. Sporn, Esq.
Vice President & General Counsel
Paul has guided TTX’s formation, patent licensure, contractor negotiations, and strategic planning. He is a seasoned corporate attorney with 20 plus years in-house experience and expertise in licensing and complex commercial transactions. Over the course of his career he has worked with multinational corporations, special purpose financing vehicles, and governmental regulatory authorities. Paul will oversee the hiring of executive officers and staff, and the execution of the TTX’s operating plan.
Daniel Mudd, MPA
Business Advisor
Daniel brings 30 years’ of executive experience leading businesses, advising boards, investors, governments, and academic institutions to TTX. He is the former Senior Vice President of General Electric and former CEO of Fortress Investment Group, and was chosen to lead Fannie Mae out of the 2008 Financial Crisis, He currently advises companies in the energy, military security, real estate, health care and finance sectors.
Sigrid Usen, Esq.
Business and Legal Advisor
Sigrid is an accomplished attorney and executive who has represented clients across a wide variety of industries including financial services, real estate, biotechnology and pharmaceuticals. She began her career at Sidley Austin and has an extensive background in corporate law, financings, mergers and acquisitions, securities, litigation, risk management and employment law. She was formerly Vice President and Senior Counsel/ High Yield Trading Floor Counsel at Merrill Lynch and also practiced at Skadden Arps. She is currently Assistant General Counsel of The RMR Group.
Dr. Andrew E. Place, MD, PhD.
Science Advisor
Co-Director of the Hematologic Malignancies Center (Clinical Service & Clinical Research) at Dana Farber Cancer Institute/Boston's Children's Hospital.
Chief Medical Officer, Institutional Centers for Clinical and Translational Research (ICCTR), Boston Children's Hospital
Associate Director, Developmental Therapeutics
Senior Physician
Assistant Professor of Pediatrics, Harvard Medical School
Alison C. Finger,
Business/Industry Advisor
Alison has over 30 years of experience successfully developing and commercializing brands that have changed clinical practice and patients’ lives. Therapeutic areas include Gene and Cell Therapy, Oncology, Neurology, Virology and Diabetes. She has launched products in the US, Europe, Asia and is recognized for her cross functional leadership spanning R&D, manufacturing, commercial launch, and operational P&L management. She currently serves as an Independent Director for ADMA Biologics and previously for Decibel Therapeutics, VBL Therapeutics, and as Chair of the Alliance for Regenerative Medicine Gene Therapy section.